K Mittal, S Donthamsetty, R Kaur,
C Yang… - British journal of …, 2017 - nature.com
Background: Docetaxel is the only FDA-approved first-line treatment for castration-resistant
prostate cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumour recurrence …